IMMURON
Immuron Ltd is a publicly listed Australian bio pharmaceutical Microbiome company focused on oral immunotherapy using polyclonal antibody products for humans. Immuron is a uniquely positioned company developing therapeutic products in NASH, ASH and other diseases mediated through gut disbiosis.
IMMURON
Industry:
Biopharma Biotechnology
Founded:
1994-01-01
Address:
Armadale, Victoria, Australia
Country:
Australia
Website Url:
http://www.immuron.com
Total Employee:
11+
Status:
Active
Contact:
+610398245254
Email Addresses:
[email protected]
Total Funding:
27.5 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS Cloudflare DNS Amazon Sydney Region Sophos
Similar Organizations
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
Current Employees Featured
Stock Details
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - Immuron
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-06 | Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer |
Official Site Inspections
http://www.immuron.com
- Host name: 104.21.86.206
- IP address: 104.21.86.206
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Immuron"
Immuron - Wikipedia
Immuron is a biotechnology company based in Melbourne, Australia. [1] In 2008, the company changed its name to Immuron Limited, [2] having previously operated as Anadis Limited. [3] …See details»
Immuron Limited
Immuron Ltd is a publicly listed Australian bio pharmaceutical Microbiome company (ASX: IMC) focused on oral immunotherapy using polyclonal antibody products for humans. Immuron is a …See details»
About Us - immuron1
Welcome to Immuron Limited. Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the …See details»
Immuron - Crunchbase Company Profile & Funding
Immuron may be growing as evidenced by the company achieving record sales for its product Travelan. The reports indicate that Immuron has seen record …See details»
Immuron Limited (IMC.AX) Company Profile & Facts - Yahoo Finance
See the company profile for Immuron Limited (IMC.AX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their ...See details»
Immuron Limited (IMRN) Company Profile & Facts - Yahoo Finance
See the company profile for Immuron Limited (IMRN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Immuron - LinkedIn
Immuron | 1,346 followers on LinkedIn. Immuron is focused on developing and commercialising products for gut mediated diseases. | Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is an Australian based and ...See details»
Immuron Limited (ASX: IMC) Company Profile & Overview - Stock …
Dec 11, 2024 Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, …See details»
Immuron Investor Centre
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a …See details»
Immuron - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 28, 2025 Immuron is a public company based in Carlton (Australia), founded in 1994.It operates as a Developer of oral immunotherapy utilizing polyclonal antibody products.See details»
Immuron Limited - VentureRadar
"Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and …See details»
Immuron Limited - AnnualReports.com
Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases.See details»
Immuron - Funding, Financials, Valuation & Investors - Crunchbase
How many investments has this organization made over time? Show . Which industries has this organization most actively invested in? Show . Announced Date . Organization Name . Lead …See details»
Immuron - Products, Competitors, Financials, Employees, …
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) Mar 5, 2025. Immuron Limited MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited …See details»
Immuron Company Profile - Office Locations, Competitors ... - Craft
Immuron has 3 employees at their 1 location and $4.9 m in annual revenue in FY 2024. See insights on Immuron including office locations, competitors, revenue, financials, executives, …See details»
Immuron 2025 Company Profile: Stock Performance & Earnings
Immuron General Information Description. Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel …See details»
Immuron - Overview, News & Similar companies | ZoomInfo.com
May 7, 2024 Who is Immuron. Founded in 1994, Immuron is a commercial and clinical-stage publicly listed Australian bio pharmaceutical company focused on developing and commerc …See details»
Immuron Limited: Shareholders, Shareholding Structure
Jan 31, 2025 Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the …See details»
Immuron (IMRN) Company Profile & Description - Stock Analysis
Apr 11, 2025 Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.See details»